In addition to Shanghai, Qinghai, Jiangsu and other places before the non-base drug bidding framework documents, Fujian Province and other provinces quietly launched the selection and preparation of the major hospital bidding procurement catalog, Jiangxi Province has also issued a document in recent days on the county and county medical institutions above the new A round of procurement catalogs are publicly supplemented.

As a pillar product of pharmaceutical companies, the resumption of non-primary drug bidding has affected the nerves of pharmaceutical companies nationwide. At present, the non-base drug bidding price reduction trend will continue, but it is generally expected that it will be better than the sharp price reductions announced at the national bidding work conference at the end of last year, and products with relatively high prices, such as individual pricing and original research drugs, will be under greater pressure. In addition, due to the adjustment of local bidding rules and local financial and other demands, brand drugs will show their advantages in the new round of non-base drug bidding.

Big standard will start

On May 4, the Jiangxi Provincial Medicine Purchasing Service Center announced the “Notice on Supplementing the Bidding Catalogue for Concentrated Procurement of Medicinal Products for Medical Institutions at the County Level and above in Jiangxi Province in 2014”, requiring companies to submit supplementary declarations to the above-mentioned catalogs. There are too many requirements for supplementary varieties, and all varieties or dosage forms that are not in the list can be declared.

Compared with the consultation draft of the tendering procurement documents for medical institutions in and above the county and county level in Jiangxi Province issued in January this year, the appendix “Bidding List Bidding Regulations (Preliminary)” has been partially adjusted, such as requiring “the same The auction team has two or more separate pricing or premium pricing, not separate groupings, etc.

“We have submitted a supplemental report and there is no product of our company in the current catalog.” Xu Hongliang, manager of marketing department of Nanchang Lijian Pharmaceuticals, told reporters that if the company submits a product that does not belong to the base medicine or “one product, two regulations, three dosages” Categories are expected to generally be added. After all, this is only a threshold for eligibility for tenders and bids. It is expected that there will still be a round of solicitation after the list is added, but the start of the bidding process is not far off.

From the national point of view, in mid-April, Fujian has quietly begun the selection of a new round of non-primary drug bidding catalogues. It is reported that non-primary drug list selection drafts and directories have been issued to commercial companies and hospitals. The varieties, specifications, and dosage forms in the catalogue can be added to meet the requirements. The selection requirements should be followed by the combination of the dosage forms. The special populations (disease types) such as pediatric diseases, psychosis, and Alzheimer's disease can be increased in size.

In addition, at present, the Guangdong Drug Electronic Trading Platform has completed the first round of bidding for non-base drugs, and the platform revealed that relevant data on non-base drug bidding will be announced in the near future. At the end of last year, Jiangsu had announced a framework document for non-base drug tenders and solicited opinions; Shanghai has not adjusted its catalogues and documents for all types of base medicines and non-base medicines, and non-base drug procurement has continued. Advancing.

According to the reporter’s understanding, Zhejiang, Anhui, and other provinces have recently conducted internal discussions on non-primary drug tendering. Some associations and business people have already participated in many related discussion meetings.

Brand drug upper position

Regarding the upcoming non-base drug bidding, Jiangxi has other business leaders who are more positive about the province's practice. It is considered a good thing for Jiangxi to seek stability in the bidding style. For example, the new document states that “separate pricing and high-quality products are not grouped separately. "The content is more fair." The state allows local exploration, but some provinces may have other considerations for tenders or innovations for a long period of time, but some innovations are not so appropriate."

Judging from the current development trend, adjustments in the general direction of bidding for generic drugs and non-base drugs have become more consistent judgments in the industry. On the one hand, the trend of substantial bargaining in the past has eased. On the other hand, it is the brand name. Generic medicines are constantly valued, and the corresponding exclusive varieties and original research varieties will continue to be under greater pressure.

In terms of prices, the two rounds of bidding for the base medicine announced by the controversial Guangdong Pharmaceutical Trading Platform model were all substantially better than the industry's expectations. The average decline of about 10% can be regarded as the smallest drop in bids for base medicines this year. At the same time, the subsequent bidding work has nothing to do with the first round, which means that the winning bid prices will not be affected by the policy factors.

In terms of quality, Qinghai and Jilin still placed the original research medicine under “the first quality level.” The rest of the provinces moved down the quality level of the original research drug, and at the same time multiplied quality stratification into the “double envelope” review. Generic drugs can Build advantages by raising other scores, such as price. The draft of Jiangsu's solicitation requires that the quality level of the generic quality assessment product and the original research drug be unified.

In terms of interviews with reporters, most of the organizations’ views are more consistent with the company's view, considering that the currently widely-viewed provinces are relatively mild and have better limits and comprehensive scores than industry expectations. The advantages of the varieties in the grouping are weakened and may be affected in the future. The grouping advantages of the original research medicines are still in place. The design of economic and technical standards has a certain tendency for high-quality varieties and large-scale enterprise products.

“Overall, there is no change in the trend of tender price cuts, but the bigger idea now is to lower the prices of high-priced medicines and explore ways to reduce the price of medicines and make hospitals, businesses and the government satisfied.” Yang Dongsheng, deputy director of the pharmaceutical market development affairs of the Chinese Association of Pharmaceutical Manufacturers of the Association of Pharmaceutical Manufacturers of China's Association of Foreign Investment Enterprises, interviewed by reporters said that in the past some practices such as Guangdong and Anhui provinces had encountered some obstacles in the implementation process and they had to make some adjustments. In the bidding for medicines, we hope that the government will consider more clinical actual conditions, including the number of medicines, the price of medicines, and the quality of medicines.